Quick answer
What are bioregulator peptides? In the published literature the phrase refers to ultrashort peptides, two to seven amino acid residues long, studied mostly by the Saint Petersburg Institute of Bioregulation and Gerontology as regulators of gene expression and protein synthesis. The best-known sequences are Ala-Glu-Asp-Gly (AEDG, epitalon), Ala-Glu-Asp (AED, sold as cartalax), Glu-Asp-Arg (EDR, sold as pinealon) and Lys-Glu (KE, sold as vilon). The reports are cell-culture, tissue and animal studies plus molecular modelling, and they are laboratory findings, not evidence of any effect in people.
Search results for "bioregulator peptides" mix scientific papers with store category pages, and the two rarely say the same thing. This guide sticks to the papers: what the term means, which sequences belong to it, what the experiments actually measured and where the evidence is thin. The material is supplied for laboratory research use only; not for human consumption.
Where the term comes from
"Peptide bioregulators" is the working vocabulary of one research network. A 2026 review from that group describes how Vladimir Khavinson proposed a concept of peptide regulation of gene expression and protein synthesis, first by preparing active peptide fractions from animal tissues and then by synthesising short peptides intended to act on specific tissues.1 The word "bioregulator" is therefore the group's own label, not a pharmacological class with a fixed membership, and a store that files a product under "bioregulators" is borrowing that label.
The common thread is size. A 2021 systematic review from the same institute defines short peptides as molecules of 2-7 residues and reports that they can penetrate cell nuclei and nucleoli and interact with nucleosomes, histone proteins and both single- and double-stranded DNA, including recognition of sequences in gene promoters.2 That proposed route, direct contact with chromatin rather than a surface receptor, is the main reason this family is discussed separately from receptor-binding research peptides.
The sequences and their masses
Most pages use market names for the sequences. The table pairs each name with its residue sequence and the computed mass from PubChem, which is the figure to compare against an identity line on a certificate.
| Market name | Sequence | Mass (g/mol) |
|---|---|---|
| Epithalon / epitalon | Ala-Glu-Asp-Gly (AEDG) | 390.35 (C14H22N4O9) |
| Cartalax | Ala-Glu-Asp (AED) | 333.29 (C12H19N3O8) |
| Pinealon | Glu-Asp-Arg (EDR) | 418.40 (C15H26N6O8) |
| Vilon | Lys-Glu (KE) | 275.30 (C11H21N3O5) |
| Studied as KED | Lys-Glu-Asp (KED) | 390.39 (C15H26N4O8) |
Two details matter at the bench. First, AEDG and KED are different compounds with almost the same mass (390.35 versus 390.39), so a mass alone cannot separate them and the stated sequence must be checked as well. Second, AED and AEDG differ by one glycine, which is why the epithalon and cartalax names are often confused. Our single-compound guides cover each one: epithalon, cartalax, pinealon and vilon.
How a peptide this small is proposed to act
Two mechanistic ideas run through the literature, and both remain proposals.
Entry into the cell
A 2022 review from the same network collects the data on how ultrashort peptides could cross membranes. It reports that carriers of the POT family (PEPT1, PEPT2, PHT1, PHT2) transport mainly di- and tripeptides into cells, and that molecular modelling and physicochemical work indicate LAT1 can carry some di- and tripeptides as well.3 The authors link this transporter route to the tissue specificity of different sequences. It is a hypothesis assembled from transporter biology and modelling, not a demonstration that each bioregulator uses a given carrier.
Contact with histones and DNA
In a 2020 study of AEDG in human gingival mesenchymal stem cells, the peptide raised mRNA expression of the neuronal markers Nestin, GAP43, beta-tubulin III and doublecortin by 1.6-1.8 times. Molecular modelling in the same paper suggested that AEDG binds preferentially to histones H1/3 and H1/6 at sites that contact DNA, and the authors proposed this as an epigenetic mechanism.4 The binding result comes from modelling, so it shows what is geometrically plausible rather than what was measured in the cells.
What the cell and animal studies reported
| Study | System | Reported result |
|---|---|---|
| Khavinson 20035 | Telomerase-negative human fetal fibroblasts | Epithalon induced telomerase catalytic-subunit expression, enzyme activity and telomere elongation |
| Al-Dulaimi 20256 | Normal and breast cancer cell lines | Dose-dependent telomere lengthening in normal cells via hTERT and telomerase; ALT activity in cancer cells |
| Ashapkin 20207 | Human fetal bone marrow mesenchymal stem cells | At nanomolar concentrations AED, KED and KE changed expression of ageing-related genes (IGF1, FOXO1, TNKS2, NFkB) |
| Anisimov 20038 | Female SHR mice, 54 per group | No change in food consumption, body weight or mean life span; differences in selected biomarkers and maximum life span |
A few of the numbers are worth reading closely. In the stem-cell work, IGF1 expression was 3.5-5.6 fold higher with the peptides, KED lowered FOXO1 expression by 1.6-2.3 fold, and AED, KED and KE all raised NFkB expression in both of the cell-ageing models used.7 In the mouse study, the epitalon group did not differ from controls in food consumption, body weight or mean life span, while chromosome aberrations in bone marrow cells fell by 17.1% and maximum life span was 12.3% longer.8 A 2020 review of the group's differentiation work adds that AEDG and AEDP induced differentiation of pluripotent cells in epidermis, mesenchyme and nervous tissue, and that the direction of differentiation depends on peptide structure and concentration.9
The 2025 telomere paper comes from an unrelated laboratory (Brunel University London) and is the most recent test of the epithalon telomerase claim in this set. It was published with a correction notice in November 2025, so anyone citing it should read the corrected version.6
Where the evidence stops
- One research network. The reviews and most primary studies cited above carry the Saint Petersburg Institute of Bioregulation and Gerontology in their author affiliations. Replication by unrelated laboratories is thin.
- In vitro and modelling. Cell lines are not tissue, and a docking result is not a binding measurement.
- Concentration and model dependence. The 2020 differentiation review and the stem-cell gene work both report that outcomes change with peptide structure, concentration and cell-ageing model, so one result does not transfer to another setup.79
- No claims about people. Review articles in this field discuss clinical use; none of that is part of this page, and none of it applies to research-grade material.
Handling and identity checks for very short peptides
A tripeptide or dipeptide behaves differently on the bench from a 30-residue peptide. Short, charged sequences are highly polar, so the chromatography method behind a purity number matters more than usual, and a single missing or extra residue changes the mass by as little as 57 g/mol (glycine). A useful certificate therefore states the sequence, the measured identity, the method and the date.
V8 lists the Epithalon product page as coming soon; it is not on sale yet, and no laboratory report is published for it today, so this page does not cite one.
Frequently asked questions
What are bioregulator peptides?
The term is used by the Saint Petersburg research group led by Vladimir Khavinson for very short peptides, two to seven amino acid residues long, that it studies as regulators of gene expression and protein synthesis. Examples are the tetrapeptide AEDG (epitalon), the tripeptides AED and EDR, and the dipeptide KE.
How is a bioregulator peptide different from a normal research peptide?
Mainly in size and in the proposed mechanism. These sequences are far shorter than peptides such as BPC-157 or ipamorelin, and the literature proposes that they act on gene expression, for example by interacting with histones and DNA, rather than only through a surface receptor.
Are bioregulator peptides proven to work?
This page describes laboratory reports only. The findings come from cell cultures, tissue explants, animal models and molecular modelling, and much of the work comes from one research network. None of it is evidence of an effect in people.
Does V8 sell bioregulator peptides?
V8 lists Epithalon (AEDG) as a coming-soon research product that is not on sale yet. The cartalax, pinealon and vilon guides are research background, not product listings. Everything V8 sells is for laboratory research use only.
Why are the molecular masses so small?
A dipeptide such as KE is about 275 g/mol and a tetrapeptide such as AEDG about 390 g/mol, against several thousand for a 29-residue peptide like sermorelin. Small, polar sequences are harder to characterise by chromatography, so the method behind a purity figure deserves a look.
Can a certificate tell me I have the right bioregulator peptide?
It can if it states the sequence, the measured identity and the method. Because several of these peptides differ by a single residue (AED versus AEDG, or KE versus KED), check that the stated sequence and mass match the compound you ordered.
References
- Arutjunyan AV, et al. Peptide Regulation of Ageing: From Experiment to Practice. Curr Aging Sci. 2026;19(1):30-41. doi:10.2174/0118746098346230250116065407; PubMed 42839866.
- Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021;26(22):7053. doi:10.3390/molecules26227053; PubMed 34834147.
- Khavinson V, Linkova N, Kozhevnikova E, Dyatlova A, Petukhov M. Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers. Int J Mol Sci. 2022;23(14):7733. doi:10.3390/ijms23147733; PubMed 35887081.
- Khavinson V, Diomede F, Mironova E, et al. AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism. Molecules. 2020;25(3):609. doi:10.3390/molecules25030609; PubMed 32019204.
- Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590-592. doi:10.1023/a:1025493705728; PubMed 12937682.
- Al-Dulaimi S, Thomas R, Matta S, et al. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025;26(5):178 (erratum: 2025;27(1):1). doi:10.1007/s10522-025-10315-x; PubMed 40908429.
- Ashapkin V, Khavinson V, Shilovsky G, Linkova N, Vanuyshin B. Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides. Mol Biol Rep. 2020;47(6):4323-4329. doi:10.1007/s11033-020-05506-3; PubMed 32399807.
- Anisimov VN, Khavinson VKh, Popovich IG, et al. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology. 2003;4(4):193-202. doi:10.1023/a:1025114230714; PubMed 14501183.
- Khavinson V, Linkova N, Diatlova A, Trofimova S. Peptide Regulation of Cell Differentiation. Stem Cell Rev Rep. 2020;16(1):118-125. doi:10.1007/s12015-019-09938-8; PubMed 31808038.
- PubChem compound records for the computed formulas and masses: Ala-Glu-Asp-Gly (CID 219042), Ala-Glu-Asp (CID 87815447), Glu-Asp-Arg (CID 10273502), Lys-Glu (CID 7010502), Lys-Glu-Asp (CID 87571363).
All V8 Peptides products are sold for laboratory research use only. They are not drugs, foods, or cosmetics and are not intended for human or animal consumption.
